Connect Biopharma (NASDAQ: CNTB) director reports initial share and option holdings
Filing Impact
Filing Sentiment
Form Type
3
Rhea-AI Filing Summary
Connect Biopharma Holdings Ltd director Kleanthis Gabriel Xanthopoulos filed an initial statement of beneficial ownership. He reports holding 80,000 Ordinary Shares directly, plus several stock options to buy Ordinary Shares with exercise prices between $0.96 and $8.16, expiring from 2030 to 2036. One option series is fully vested and exercisable, while another fully vests and becomes exercisable on March 2, 2027.
Positive
- None.
Negative
- None.
Insider Trade Summary
8 transactions reported
Mixed
8 txns
Insider
Xanthopoulos Kleanthis Gabriel
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 89,220 shares (Direct);
Ordinary Shares — 80,000 shares (Direct)
Footnotes (1)
- The stock option is fully vested and exercisable. The stock option fully vests and becomes exercisable on March 2, 2027.
FAQ
What does the CNTB Form 3 filing by Kleanthis Gabriel Xanthopoulos show?
The Form 3 shows Xanthopoulos’ initial holdings in Connect Biopharma. He reports 80,000 Ordinary Shares held directly and multiple stock options for additional Ordinary Shares at set exercise prices and future expiration dates.
What stock options are reported in the CNTB Form 3 for Xanthopoulos?
The filing lists several stock options on Ordinary Shares with exercise prices ranging from $0.96 to $8.16. These options have expiration dates between 2030 and 2036 and represent rights to acquire additional shares in the future.
Are any of Xanthopoulos’ CNTB stock options already vested and exercisable?
Yes, one stock option series is fully vested and exercisable according to the filing. Another option series is scheduled to fully vest and become exercisable on March 2, 2027, providing additional potential future share ownership.
Does the CNTB Form 3 indicate any recent buy or sell transactions by Xanthopoulos?
No recent buy or sell transactions are indicated in this Form 3. It serves as an initial ownership report, detailing existing Ordinary Share holdings and outstanding stock options rather than new market purchases or sales.
Is Xanthopoulos’ ownership in CNTB held directly or through other entities?
The filing shows Xanthopoulos’ holdings as directly owned. Both the 80,000 Ordinary Shares and the reported stock options are listed as direct ownership, with no trusts or other intermediary entities referenced in the data provided.